

February 3, 2021
Sysmex Corporation

Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.; hereinafter, "Siemens Healthineers") today announced that, on February 2, 2021, the two companies agreed to extend their long-standing alliance on global supply, distribution, and sales and service for hemostasis products through at least 2023. The agreement enables global laboratory customers to continue to benefit from the world's largest portfolio of hemostasis systems and reagents.

For more than 20 years since signing the global alliance agreement on hemostasis products in 1995, the two companies have built a solid partnership. The extension of the agreement will continue to allow Sysmex and Siemens Healthineers to mutually supply hemostasis systems and reagents, respectively, on a global basis, thus achieving the world's most extensive product portfolio that caters to laboratory customers' diverse needs.

The renewed agreement contains a partial review of the list of products and territories for mutual supply. Sysmex hopes that it will reinforce the sales of Sysmex's CN-Series automated blood coagulation analyzer and allow the two companies to maintain the proven cooperative framework to offer ample solutions for hemostasis testing to customers the world over. Sysmex and Siemens Healthineers will continue to harness each other's strengths to expand the hemostasis business, with a view toward contributing to the standardization and enhanced quality of hemostasis testing.

Overview of the Agreement

Date of agreement:	February 2, 2021
Content:	Mutual supply, distribution, and sales and service for hemostasis products
Duration:	February 1, 2021 through December 31, 2023
Territories:	Worldwide

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan,

has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its affiliate companies, please visit <http://www.sysmex.co.jp/en/>.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.

Information contained in the press release is current as of the date of the announcement but may be subject to change without prior notice.